Accéder au contenu
Merck

Leishmania in HLH: a rare finding with significant treatment implications.

Journal of pediatric hematology/oncology (2013-03-21)
Gurpreet Singh, Meer-Taher Shabani-Rad, Otto G Vanderkooi, Joseph V Vayalumkal, Susan M Kuhn, Gregory M T Guilcher, MacGregor Steele
RÉSUMÉ

Hemophagocytic lymphohistiocytosis (HLH) associated with visceral leishmaniasis (VL) is a very rare phenomenon. We report the first known North American case in a 21 month old boy. He was initially diagnosed with Epstein Barr virus (EBV) triggered HLH and treated with the international treatment protocol, HLH-2004. Stem cell transplant was planned due to repeated reactivations of disease, but his pretransplant bone marrow revealed an unexpected protozoan-Leishmania donovani. Treatment with liposomal amphotericin B led to resolution of all manifestations of HLH. We discuss how the clinical and laboratory features of both entities can closely mimic each other and are extremely difficult to differentiate. This case also raises the question of whether to screen all children with suspected HLH for Leishmania in a non endemic area.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Amphotéricine B solution, 250 μg/mL in deionized water, 0.1 μm filtered, BioReagent, suitable for cell culture
Sigma-Aldrich
Amphotéricine B solubilisée, powder, γ-irradiated, BioXtra, suitable for cell culture
Sigma-Aldrich
Amphotéricine B from Streptomyces sp., ~80% (HPLC), powder
Sigma-Aldrich
Amphotéricine B from Streptomyces sp., BioReagent, suitable for cell culture, ~80% (HPLC)
Amphotericin B for peak identification, European Pharmacopoeia (EP) Reference Standard